Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, received FDA approval in 2010 to improve glycemic control in adults with T2D, with a post-marketing requirement to conduct a randomized, double-blind, controlled trial evaluating the effect of liraglutide on the incidence of major adverse cardiovascular events (MACE). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.